In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
News|Podcasts|October 14, 2026
ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
her October column , Rebecca Johnson, PhD, argues that representation gaps are built into protocol design, eligibility criteria, and site placement decisions long before recruitment begins. Only 24% of sponsors systematically benchmark disease demographics against enrolled populations, and sites remain clustered in urban areas while patients routinely travel more than 50 miles to participate. Johnson proposes an inclusion-by-design framework that treats representation as a foundational input rather than an operational overlay. IgniteData and RealTime eClinical Solutions announced a partnership enabling sites to transfer clinical data directly from eSource platforms to sponsor electronic data capture systems, eliminating manual transcription between systems. RealTime serves more than 3,000 research sites across 30 countries, while Archer is deployed at 80% of the National Cancer Institute's Designated Cancer Centers. The integration reduces coordinator burden and allows sponsors to accelerate data acquisition timelines.Roche licensed an RNAi candidate targeting ALK7 from Rona Therapeutics for obesity under a deal worth up to $100 million upfront and up to 1.06 billion dollars in additional milestone payments. ALK7, expressed in adipose tissue, reduces visceral and ectopic fat while preserving lean mass through direct tissue targeting rather than appetite suppression. The mechanism positions it as potentially complementary to existing GLP-1 therapies.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
In today’s ACT Brief, we examine how legacy workflows pull community clinics away from patient care, why medical writing capacity depends on training rather than technology, and how an antiviral aims to prevent COVID-19 after exposure
In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
Trending on Applied Clinical Trials Online
1
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
ACT Brief: Embedding AI Across Operations, Faster Trial Decisions, and Voceryq Approval
5